Regeneron Pharmaceuticals, Inc. (REGN) Stock

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is led by CEO Leonard S. Schleifer, employs 15,158 people, headquartered in Tarrytown, US, publicly traded since 1991.

Regeneron Pharmaceuticals, Inc. (REGN) stock trades at $805.02 with a market capitalization of $82.88B. The stock is valued at a price-to-earnings (P/E) ratio of 18.82, price-to-book of 2.57, price-to-sales of 5.23. Over the past 52 weeks the stock has ranged between $541.00 and $859.34, and currently trades 6.3% below its 52-week high. It pays a dividend yielding 0.48%.

On profitability, Regeneron Pharmaceuticals, Inc. generates a return on equity (ROE) of 13.81%, return on capital employed of 10.97%, an operating margin of 24.95%, a net profit margin of 27.86%.

In its most recent fiscal year, Regeneron Pharmaceuticals, Inc. reported annual revenue of $14.3B, net profit of $4.5B. Over the last 5 fiscal years, revenue grew at an average annual rate of 11.0%, and net profit grew at an average annual rate of 5.1%.

The balance sheet shows a debt-to-equity ratio of 0.06 (debt below half of shareholders' equity), a current ratio of 4.13, total assets of $40.6B, $3.1B in cash and equivalents.

REGN has a beta of 0.24 (historically less volatile than the overall market).

Regeneron Pharmaceuticals, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Regeneron Pharmaceuticals, Inc. reported revenue of $4.9B rising to $14.3B, a change of +195.1% across 10 years. Compounded, revenue has grown 11.0% a year over five years, 5.6% over three, 1.0% over the last twelve months. Net profit rose to $4.5B.

Operating margin went from 27.4% in 2016 to 24.9% in 2025, a fall of 2.4 percentage points. The most recent net margin is 27.86%. On a trailing twelve-month basis to Jun '26, revenue is $15.5B and net profit $4.3B.

Borrowings rose from $481.0M to $2.7B, cash from operations was $5.0B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 21.4% over five years, and was 14.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Regeneron Pharmaceuticals, Inc. (REGN) — frequently asked questions